Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced liver disease.

W Mayoral1, J H Lewis, H Zimmerman

  • 1Georgetown University Medical Center, Washington, DC, USA.

Current Opinion in Gastroenterology
|October 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

McSART: an iterative model-based, motion-compensated SART algorithm for CBCT reconstruction.

Physics in medicine and biology·2019
Same author

A prospective gating method to acquire a diverse set of free-breathing CT images for model-based 4DCT.

Physics in medicine and biology·2018
Same author

SU-E-J-210: Lung Tumor Target Volume Contours on EPID Cine Mode Images.

Medical physics·2017
Same author

3D fluoroscopic image estimation using patient-specific 4DCBCT-based motion models.

Physics in medicine and biology·2015
Same author

Correlation of two-photon in vivo imaging and FIB/SEM microscopy.

Journal of microscopy·2015
Same author

Letter: antibiotic dose adjustment in patients with advanced liver disease--authors' reply.

Alimentary pharmacology & therapeutics·2013
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

New drug-induced liver injury reports highlight severe hepatic necrosis and vanishing bile duct syndrome. Physicians and patients must be aware of risks with both new and old medications, especially in those with liver disease.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Drug Safety

Background:

  • Recent years have seen new drug additions causing severe hepatic injury, including fulminant hepatic necrosis.
  • Some hepatotoxic drugs have been withdrawn from the market, while others now carry stringent monitoring guidelines.
  • Vanishing bile duct syndrome is increasingly recognized, with over 30 associated drugs, including newly reported cases linked to ibuprofen.

Purpose of the Study:

  • To review recent developments in drug-induced hepatic injury.
  • To highlight emerging patterns of hepatotoxicity, such as vanishing bile duct syndrome.
  • To discuss the implications for drug safety and patient management, particularly for those with pre-existing liver conditions.

Main Methods:

  • Review of recent scientific literature and case reports on drug-induced liver injury.

Related Experiment Videos

  • Analysis of newly identified hepatotoxic agents and their clinical presentations.
  • Examination of risk factors and specific syndromes associated with drug hepatotoxicity.

    • Main Results:

    • Several new drugs have been identified as causing hepatic injury, some leading to market withdrawal.
    • Vanishing bile duct syndrome is now linked to over 30 drugs, with ibuprofen being a recent addition.
    • Hepatitis C virus infection may increase the risk of ibuprofen-induced liver injury, underscoring concerns for patients with underlying liver disease.

    Conclusions:

    • Continuous vigilance is required to identify and manage drug-induced hepatic injury.
    • The spectrum of drug hepatotoxicity is evolving, necessitating updated clinical awareness and monitoring.
    • Safe prescribing practices are crucial, especially for patients with pre-existing liver conditions, considering both prescription and nonprescription medications.